Neng Jiang | Biochemistry | Best Researcher Award

Dr. Neng Jiang | Biochemistry | Best Researcher Award

Sun Yat-sen University Cancer Center | China

Dr. Neng Jiang is a highly accomplished pathologist and cancer researcher, recognized for his expertise in angiogenesis and stem cell biology within the context of lung cancer. With both an MD and a Ph.D., he has established himself as a leading academic and clinical researcher at the Department of Pathology, Sun Yat-sen University Cancer Center in Guangzhou, China, one of Asia’s foremost institutions for oncology research. His career is defined by a commitment to advancing diagnostic pathology and deepening the understanding of cancer mechanisms, with a focus on bridging molecular discoveries with real-world clinical applications. Over the years, Dr. Jiang has authored multiple publications in high-impact international journals indexed in Scopus, PubMed, and Web of Science, contributing valuable knowledge to the global medical community. His ability to integrate clinical observations with experimental research has positioned him as a crucial contributor to translational oncology, enabling better strategies for early detection and targeted therapies. Through international collaborations and active engagement in academic forums, he has established a strong global presence. With a career dedicated to advancing cancer research and improving patient outcomes, Dr. Jiang exemplifies the role of a researcher whose work drives innovation, education, and clinical transformation in modern oncology.

Professional Profile

Education

Dr. Neng Jiang’s academic foundation is firmly rooted in medicine and research, reflecting his dual training as a clinician and scientist. He pursued his Doctor of Medicine (MD) with a specialization in pathology, equipping him with extensive knowledge of human disease processes and diagnostic methodologies. Following his medical degree, he undertook a Doctor of Philosophy (Ph.D.) in Oncology and Pathology, which allowed him to explore advanced mechanisms of cancer development, particularly angiogenesis and cancer stem cell biology. His Ph.D. research, conducted at Sun Yat-sen University Cancer Center, emphasized the tumor microenvironment and molecular factors influencing cancer progression, with findings that contributed to the academic literature in the field. Throughout his education, Dr. Jiang actively engaged in research activities, conference presentations, and collaborative projects, which strengthened both his theoretical and practical understanding of oncology. His commitment to academic excellence is reflected in his strong track record of publications during his doctoral studies. By combining clinical medical training with rigorous scientific inquiry, Dr. Jiang’s education uniquely prepared him to bridge the gap between laboratory research and patient care, laying the foundation for his impactful career in pathology and oncology research at national and international levels.

Professional Experience

Dr. Neng Jiang’s professional career has been characterized by his contributions to both clinical pathology and academic research. He currently serves at the Department of Pathology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, one of the most prestigious oncology research institutions in China. In this role, he has been deeply involved in diagnostic pathology while leading projects that investigate the biological basis of cancer progression. His experience extends across collaborative clinical studies, translational research, and guiding younger researchers in pathology-related investigations. Dr. Jiang has worked extensively with multidisciplinary teams, both domestically and internationally, enabling him to contribute to projects that integrate clinical practice with laboratory innovation. His professional portfolio includes participation in major research initiatives aimed at improving cancer diagnostics, treatment strategies, and biomarker discovery. He has also presented his work at leading scientific conferences, where he has shared critical insights with the global pathology and oncology community. Beyond his research and clinical commitments, Dr. Jiang plays a role in academic mentorship, training medical students and junior researchers, thereby fostering the next generation of cancer scientists. His professional journey highlights a balance of leadership, innovation, and dedication to advancing oncology.

Research Interests

Dr. Neng Jiang’s primary research interests lie at the intersection of angiogenesis, stem cell biology, and lung cancer pathology, areas that are central to understanding tumor initiation, growth, and metastasis. He has a particular focus on the molecular pathways and tumor microenvironmental factors that drive cancer progression, with the ultimate aim of developing more effective therapeutic interventions. His work explores how abnormal vascular growth supports cancer survival and how cancer stem cells contribute to resistance to therapy and recurrence. In addition to lung cancer, he has engaged in research that evaluates biomarkers for cancer diagnosis and prognosis, contributing to precision medicine approaches in oncology. Dr. Jiang’s research interests also include translational applications, where discoveries in the laboratory are applied to clinical settings, bridging the gap between basic science and patient care. By combining pathology expertise with molecular research, he aims to identify novel targets for anti-cancer therapies and improve strategies for early cancer detection. His dedication to these research areas is evident in his growing body of publications in high-impact journals and his collaborations with international experts. This focus ensures that his work continues to make meaningful contributions to both academic research and clinical oncology practice.

Research Skills

Over the course of his academic and professional career, Dr. Neng Jiang has developed an extensive range of research skills that make him highly effective in cancer pathology and translational oncology. His expertise spans both laboratory-based and clinical methodologies. He is proficient in histopathology, immunohistochemistry, molecular diagnostics, and biomarker analysis, enabling him to provide detailed insights into tumor biology. Dr. Jiang has also mastered experimental techniques related to cell culture, angiogenesis assays, and stem cell studies, which are vital for investigating mechanisms of tumor growth and resistance. Beyond laboratory skills, he has strong experience in scientific writing, data interpretation, and statistical analysis, ensuring his research is rigorous and impactful. His ability to integrate clinical observations with molecular-level data distinguishes his work and allows him to develop comprehensive approaches to cancer research. Additionally, Dr. Jiang is adept at working in multidisciplinary research environments, coordinating with oncologists, molecular biologists, and clinicians to achieve common goals. He also has experience with international research platforms, presenting findings at conferences and contributing to global scientific dialogues. These skills, combined with his clinical training, position him as a well-rounded researcher capable of delivering impactful contributions to modern oncology.

Awards and Honors

Throughout his career, Dr. Neng Jiang has received recognition for his outstanding contributions to pathology and oncology research. His awards reflect both academic excellence and research innovation. He has been acknowledged for his impactful publications in high-impact journals, many of which focus on lung cancer pathology, angiogenesis, and stem cell biology. His work has contributed to the development of novel diagnostic and therapeutic approaches, earning him recognition at both national and international scientific forums. Dr. Jiang has also been invited to present his findings at leading conferences, where his presentations have received commendation for advancing the field of oncology. In addition to publication-related achievements, he has been honored with institutional awards from Sun Yat-sen University Cancer Center, recognizing his leadership and research excellence. His active participation in academic committees and professional societies has further solidified his standing as a respected member of the scientific community. While his career continues to evolve, the honors he has already received demonstrate his capacity for innovation, his dedication to patient-centered research, and his role as a thought leader in cancer pathology. These recognitions highlight his potential for future breakthroughs and leadership in global oncology research.

Publication Top Note

  • Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy — 2025

Conclusion

In conclusion, Dr. Neng Jiang is a distinguished pathologist and oncology researcher whose career reflects a remarkable blend of academic excellence, clinical expertise, and research innovation. With his dual qualifications of MD and Ph.D., he has developed an in-depth understanding of cancer biology, particularly focusing on angiogenesis and stem cell pathways in lung cancer. His research contributions, published in reputed journals and presented at international conferences, have advanced knowledge in cancer pathology and created new avenues for therapeutic strategies. Professionally, he has played a critical role at the Sun Yat-sen University Cancer Center, where he combines clinical diagnostics with pioneering research initiatives. His skills in molecular diagnostics, translational research, and scientific leadership make him a valuable contributor to both academia and clinical oncology. Recognized with multiple awards and honors, Dr. Jiang’s career demonstrates consistent excellence and a commitment to improving patient outcomes. Looking forward, his ongoing dedication to research and collaboration promises further advancements in cancer detection and treatment. These qualities make him a deserving candidate for international recognition, particularly the Best Researcher Award, as he continues to shape the future of pathology and oncology at both national and global levels.

Aurora Daniele | Biochemistry | Best Researcher Award

Prof. Dr. Aurora Daniele | Biochemistry | Best Researcher Award

University of Naples Federico II | Italy

Prof. Dr. Aurora Daniele is an accomplished academic and researcher with more than three decades of contributions to the fields of molecular biology, genetics, and biochemistry. Currently serving as a Full Professor at the Università degli Studi di Napoli “Federico II,” she has established herself as an influential figure in biomedical sciences with a broad focus ranging from enzymatic pathways and protein biosynthesis to lysosomal storage disorders and molecular diagnostics. Her career reflects a remarkable blend of academic leadership, impactful research, and international collaboration. Prof. Daniele has published extensively in top-tier journals, authoring over 136 scientific papers indexed in Scopus, Web of Science, and PubMed. With an h-index of 30 and more than 2,700 citations, her research is widely recognized and cited globally. She has collaborated with institutions such as the Mayo Clinic in the United States and played a pivotal role as Principal Investigator at CEINGE – Biotecnologie Avanzate. Beyond research, she has contributed to academic governance, serving as President of the School of Food and Nutrition Sciences at the University of Campania “L. Vanvitelli.” Through her outstanding work, Prof. Daniele has significantly advanced knowledge in life sciences while shaping the next generation of scholars and practitioners.

Professinal Profile

Scopus | ORCID

Education

Prof. Dr. Aurora Daniele’s academic journey began with a strong foundation in the life sciences. She pursued her degree in Biological Sciences at the Università degli Studi di Napoli “Federico II,” where she developed a keen interest in molecular biology, genetics, and biochemical research. Her rigorous training at this historic university provided her with both theoretical depth and practical expertise, enabling her to engage in cutting-edge research from the early stages of her career. Following her initial studies, she sought advanced scientific exposure through national and international fellowships, most notably at the Telethon Institute of Genetics and Medicine in Milan, Italy. During this formative period, she focused on molecular diagnostics, genetic regulation, and the study of metabolic pathways. These opportunities enriched her scientific outlook, broadening her expertise in clinical molecular biology and the application of advanced biotechnological methods. Her educational background, deeply rooted in one of Italy’s oldest and most prestigious institutions, provided the strong academic and research orientation that continues to guide her career today. This blend of local academic grounding and global research training has allowed Prof. Daniele to establish herself as a thought leader in genetics and molecular diagnostics.

Professional Experience

Prof. Dr. Aurora Daniele has an extensive record of academic leadership and professional achievements. She currently serves as Full Professor at the Università degli Studi di Napoli “Federico II,” where she has taught and mentored undergraduate, graduate, and doctoral students in life sciences, biochemistry, and genetics. Her professional trajectory includes notable leadership roles, such as her tenure as President of the School of Food and Nutrition Sciences at the University of Campania “L. Vanvitelli”. In addition, she has contributed significantly to clinical and translational research as Principal Investigator at CEINGE – Biotecnologie Avanzate, an advanced biotechnology research center in Naples. Her professional career has been marked by consistent efforts to integrate molecular diagnostics into clinical applications, advancing both science and healthcare. Prof. Daniele has also played an essential role in fostering collaborations with international institutions, including the Mayo Clinic in the United States, thereby broadening the impact of her research beyond Italy. As an educator and scientist, she has successfully combined laboratory innovation with academic leadership, resulting in a career that influences policy, teaching, and medical practice. Her professional achievements highlight her as a leader in Italian and international biomedical research.

Research Interests

Prof. Dr. Aurora Daniele’s research interests lie at the intersection of molecular biology, genetics, and clinical biochemistry. Her work primarily focuses on enzymatic pathways, protein biosynthesis, and the molecular mechanisms underlying lysosomal storage disorders. She has dedicated significant research efforts to understanding genetic regulation and transcriptomic responses, with particular attention to the signaling pathways involved in metabolic and degenerative diseases. Another central aspect of her research is the development and application of molecular diagnostic tools aimed at identifying genetic disorders and optimizing clinical interventions. She is equally interested in transcriptomic and proteomic studies, which provide a broader systems-level understanding of disease pathophysiology. Over the years, Prof. Daniele has expanded her research to include clinical molecular diagnostics, with an emphasis on bridging laboratory science and patient care. She has also contributed to the study of nutritional sciences, linking metabolism to molecular pathways, thereby highlighting the interplay between diet, genetics, and health outcomes. Her wide-ranging interests have allowed her to contribute meaningfully to both fundamental science and applied medicine, positioning her as a key figure in advancing knowledge in biomedicine, diagnostics, and personalized healthcare.

Research Skills

Prof. Dr. Aurora Daniele possesses a highly diverse and advanced skill set in molecular biology, biochemistry, and genetics. She is proficient in enzymatic assays, protein expression and purification techniques, and the analysis of signaling pathways critical to cellular function. Her expertise extends to transcriptomic and proteomic technologies, enabling her to study gene expression regulation and protein interactions at a systems biology level. Additionally, she has advanced skills in clinical molecular diagnostics, which she has applied in both laboratory and translational settings to improve the detection and understanding of genetic disorders. Prof. Daniele is skilled in molecular cloning, PCR, electrophoresis, and biochemical analysis of cellular mechanisms. Her research also demonstrates proficiency in developing and validating biomarkers for disease, particularly in lysosomal storage disorders. Beyond laboratory methods, she is adept at scientific writing, project leadership, and cross-disciplinary collaboration, often integrating expertise from different research domains. Her ability to combine technical precision with conceptual innovation has made her a valuable contributor to both basic and applied research. These skills, acquired over decades of work, form the backbone of her impactful contributions to modern biomedical sciences.

Awards and Honors

Throughout her career, Prof. Dr. Aurora Daniele has received recognition for her exceptional contributions to biomedical research and academic leadership. She has been consistently acknowledged for her role in advancing molecular biology and clinical biochemistry, as well as for her leadership positions within prestigious Italian universities. Serving as President of the School of Food and Nutrition Sciences at the University of Campania “L. Vanvitelli” reflects her academic excellence and administrative capabilities. Her extensive publication record, with over 136 papers indexed in Scopus, PubMed, and Web of Science, further testifies to her global recognition. With an h-index of 30 and over 2,700 citations, her influence within the scientific community is substantial. Beyond metrics, she has been invited to collaborate with international research institutions, including the Mayo Clinic, underscoring the value of her expertise in global biomedical research. While specific awards and formal honors add to her distinction, her career itself stands as a testament to sustained excellence, mentorship, and leadership. Her recognition is rooted not only in academic circles but also in her meaningful impact on advancing diagnostics, therapeutic strategies, and higher education.

Publication Top Notes

  • Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study — 2025

  • β-Hydroxybutyrate mitigates the detrimental effects of high glucose in human retinal pigment epithelial ARPE-19 cells — 2025

  • Adiponectin and HMW Oligomers in Relation to Inflammatory Markers in Crohn’s Disease Patients — 2025

  • Plasma adiponectin levels are associated with habitual dietary polyphenol intake in individuals at high cardiometabolic risk: a cross-sectional study — 2025

  • Exploring the Link Between Psoriasis and Adipose Tissue: One Amplifies the Other — 2024 — 2 citations

  • Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue — 2024 — 3 citations

  • Effects of Exhaustive Exercise on Adiponectin and High-Molecular-Weight Oligomer Levels in Male Amateur Athletes — 2024 — 1 citation

  • LncRNA microarray profiling identifies novel circulating lncRNAs in hidradenitis suppurativa — 2024 — 3 citations

Conclusion

Prof. Dr. Aurora Daniele exemplifies the qualities of an outstanding researcher, educator, and leader in the fields of molecular biology, genetics, and biochemistry. With a career spanning more than three decades, she has consistently contributed to advancing both fundamental science and applied clinical practices. Her extensive research output, collaborations with international institutions, and leadership roles within Italian academia reflect her ability to integrate innovation, mentorship, and governance. She has effectively bridged laboratory research with healthcare applications, particularly in molecular diagnostics and metabolic disorders, thereby enhancing both scientific understanding and patient outcomes. Her skills, ranging from enzymatic assays to proteomic studies, highlight her versatility and technical excellence, while her publication record demonstrates her influence and recognition within the global scientific community. Prof. Daniele’s dedication to education has further amplified her impact, preparing the next generation of scientists and healthcare professionals. Her professional journey underscores a balance of academic rigor, international collaboration, and scientific creativity, making her a true leader in biomedical sciences. With her ongoing research and visionary outlook, she continues to shape the future of diagnostics, molecular medicine, and higher education, deserving recognition at the highest levels.

Fu Xiaocong | Molecular Biology | Best Innovation Award

Mr. Fu Xiaocong | Molecular Biology | Best Innovation Award

Shanghai Paisi Xin Biopharmaceutical Technology Co., Ltd. Malaysia

Dr. Xiaocong Fu is a highly accomplished Senior Tumor Immunology Researcher with more than a decade of experience in the development of cell therapy and gene/nucleic acid-based therapeutics. Currently based in Shanghai, he holds a PhD and has served in both academic and industrial roles, including as Founder of PSM Biotech and Associate Professor at Taylor’s University. His career encompasses a broad range of translational research activities with a strong focus on clinical immunology, drug mechanism validation, and precision oncology. He has published over 30 academic papers, with 13 as the first author in SCI-indexed journals, and holds more than nine personal invention patents. Dr. Fu is certified in GCP, CAP auditing, and biosafety regulations, with additional advisory roles in AI research and biotechnology projects. His multifaceted expertise includes immune function analysis, CAR-T/TCR-T method development, and organoid model systems, all of which reflect his dedication to innovation and real-world impact. His unique ability to combine clinical relevance with scientific discovery positions him as a leading figure in the field of tumor immunology and a strong candidate for prestigious innovation and research awards.

Professional Profile

Education

Dr. Xiaocong Fu holds a Doctorate in Tumor Immunology, which has laid the scientific foundation for his highly specialized career in immunotherapy research. In addition to his academic training in immunology, he pursued advanced studies in business and innovation management at the China Europe International Business School, equipping him with a strategic understanding of biotech commercialization and research leadership. This interdisciplinary educational background has uniquely positioned him to integrate laboratory innovation with real-world therapeutic applications. His formal training includes rigorous technical and regulatory coursework, exemplified by certifications in Good Clinical Practice (GCP) and clinical trial quality management. Dr. Fu has also completed specialized training in biosafety and laboratory quality systems, including certification from the Shanghai Biosafety Training and Assessment Program and the College of American Pathologists (CAP). These credentials have enabled him to oversee clinical laboratory standards and contribute to high-stakes regulatory audits and clinical research. His academic affiliation with Taylor’s University as an Associate Professor further demonstrates his commitment to continuous learning, academic mentorship, and scientific excellence. The combination of scientific rigor and managerial insight distinguishes Dr. Fu’s educational journey and reflects his preparedness to drive complex, multidisciplinary projects in immunology and therapeutic development.

Professional Experience

Dr. Xiaocong Fu’s professional journey spans more than a decade of progressive responsibility in both industry and academia, reflecting a strong blend of translational research and entrepreneurial leadership. From 2012 to 2019, he worked at Shanghai WuXi AppTec Co., Ltd., where he played a critical role in preclinical and clinical immunology research. His responsibilities included the development of orthotopic tumor models, pharmacokinetic/pharmacodynamic studies, immune function assays, and clinical biomarker validation. During this time, he built expertise in flow cytometry, immune subpopulation analysis, and organoid construction platforms. As Technical Director of the CAP Clinical Center, Dr. Fu successfully developed and validated multiple clinical methods, including those for CAR-T therapies and phosphorylation-related biomarker detection. His current roles include Founder of PSM Biotech, where he leads innovation in cell and gene therapy platforms, and Associate Professor at Taylor’s University, where he contributes to academic research and mentorship. He also serves as Vice President of the Jiangxi Chamber of Commerce and holds advisory roles with AI research institutes. Dr. Fu’s professional scope covers scientific innovation, quality control, clinical trial management, and biotech entrepreneurship, establishing him as a multifaceted leader in the biomedical and pharmaceutical research sectors.

Research Interests

Dr. Xiaocong Fu’s research interests lie at the forefront of tumor immunology, cell therapy development, and translational clinical science. His primary focus is on understanding the mechanisms of immune response in cancer, particularly through the development and validation of CAR-T and TCR-T therapies. He is deeply involved in immune-mediated killing analyses, including ADCC (antibody-dependent cellular cytotoxicity), CDC (complement-dependent cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), and TLR (toll-like receptor) functions. Dr. Fu also explores immune phenotyping and biomarker discovery, especially in relation to hematological malignancies and solid tumors. Another key area of interest is the use of induced pluripotent stem cells (iPSCs) for disease modeling and drug response simulation, with his team constructing organoid platforms for more precise in vitro analyses. Additionally, he is passionate about integrating gene editing technologies such as CRISPR to develop immune cell-based models that mimic in vivo responses. Dr. Fu’s interests extend to clinical pharmacology, biomarker-based patient stratification, and receptor occupancy studies, all aimed at creating more effective, personalized therapeutic strategies. His research is inherently translational, bridging the gap between laboratory innovation and clinical application to improve patient outcomes in cancer immunotherapy.

Research Skills

Dr. Xiaocong Fu possesses a wide array of advanced research skills that make him a standout contributor in the field of tumor immunology and clinical translational research. He is proficient in both in vitro and in vivo assays, including the development of orthotopic tumor models and functional immune assays. He has mastered multiparameter flow cytometry and is capable of operating high-throughput cytometry instruments such as the BD Fortessa X-20 and Canto systems, applying panels with up to 18 colors. His skill set includes the quantitative analysis of intracellular and extracellular signaling molecules, using detection platforms like Cytometric Bead Array (CBA) and Meso Scale Discovery (MSD). Dr. Fu is experienced in gene editing using CRISPR/Cas9 technologies, having successfully developed monoclonal iPSCs with precise gene knock-ins/knockouts. In clinical pharmacology, he has validated several PK/PD methods for CAR-T therapies and phosphorylation biomarkers. His technical leadership extends to immunophenotyping of both lymphoid and myeloid subpopulations, receptor occupancy assays, and biomarker tracking. He is also adept at clinical laboratory quality systems, having contributed to CAP audits and biosafety program implementations. These diverse, high-level research skills have enabled him to lead multidisciplinary projects across discovery, validation, and clinical translation domains.

Awards and Honors

Throughout his career, Dr. Xiaocong Fu has received numerous accolades that highlight his commitment to excellence and innovation in biomedical research. While specific award titles are not listed in the provided profile, his recognition can be inferred from his leadership roles and scientific achievements. His appointment as an Associate Professor at Taylor’s University, a position typically awarded to individuals with significant academic contributions, underscores his research credibility. His selection as a CAP auditor and a GCP-certified clinical trial manager reflects the high level of trust regulatory and research bodies place in his judgment and technical competence. As the Founder of PSM Biotech, he has also been acknowledged for his entrepreneurial efforts in translating immunological science into therapeutic platforms. Moreover, his advisory role in AI-based scientific projects further demonstrates peer recognition of his interdisciplinary expertise. With over 13 first-author SCI publications and nine personal invention patents, Dr. Fu’s body of work stands as a testament to sustained scholarly and innovative output. These milestones serve as informal yet powerful recognitions of his contributions, suggesting that he is not only a subject matter expert but also a recognized leader in his field.

Conclusion

Dr. Xiaocong Fu exemplifies the fusion of scientific excellence, clinical relevance, and innovative thinking necessary to transform cancer therapy through immune system modulation. His rich educational background, expansive professional experience, and cutting-edge research portfolio position him at the forefront of biomedical innovation. From pioneering CAR-T and TCR-T therapies to constructing iPSC-based organoid models, his work covers the full spectrum of research from basic science to translational application. As a skilled researcher, technical leader, and biotech entrepreneur, Dr. Fu has developed and validated multiple clinical methodologies, driven discovery in tumor immunology, and fostered collaborations across academia, industry, and regulatory agencies. His research consistently addresses real-world challenges in oncology and immunotherapy, leveraging both molecular precision and systems-level insight. Although there is room to expand his visibility in global academic networks and enhance commercialization outcomes, Dr. Fu’s existing contributions are both impactful and future-focused. He is a model candidate for honors such as the Best Innovation Award in Research and represents the caliber of researcher who not only advances knowledge but also changes lives through science.